Phase 2 Clinical Trial Opens At Imperial College London

Achillion Pharmaceuticals is currently carrying out phase 2 clinical trials of their drug ACH-0144471, a Factor D inhibitor with the aim of treating C3G.

For more details including inclusion and exclusion criteria for the trial please follow this link to clinicaltrials.govĀ

As you will see there are multiple locations/centres for the trial throughout the world including one in the UK. If you are interested in taking part in the trial and are UK based please get your nephrologist to contact Professor Liz Lightstone PhD FRCP at Imperial College London via e-mail at

Non UK patients can find trial location information on Achillion can be contacted on 2037525566 or





Get the latest

For up-to-date news and information visit our news or join our mailing list below:

Join us, it's free!

Upcoming events

View upcoming events and dates in our MPGN/DDD Support Group calendar.

View Calendar


Find out what we’re doing right now and how you can help:

Read more